Despite the Hospital Transparency Rule being in effect, the majority of 340B hospitals are not reporting their prices for top services and drugs, and those that have, reported on “egregious” markups, said Ted Okon, MBA, executive director, Community Oncology Alliance.
Despite the Hospital Transparency Rule being in effect, the majority of 340B hospitals are not reporting their prices for top services and drugs, and those that have, reported on “egregious” markups, said Ted Okon, MBA, executive director, Community Oncology Alliance (COA).
Transcript
The Hospital Transparency Rule has been in effect for over a year now, and COA has pointed out the widespread failure of many 340B hospitals to follow this rule. Where do you go from here?
HHS requires that hospitals disclose, in an easy manner, basically, their prices on top services and drugs. And last year, when [COA] had [Dr] Ronny Gal's Moto [Bio]advisors look at this, we found that of the over 1000 340B hospitals, only 11% were reporting their data. What that showed, though, with that 11% is they're marking up drugs 3.8 times. Not 3.8%, 3.8 times. And that's just egregious, especially when they have these 340B discounts.
So, the end result of that is that we now see more hospitals reporting; we're actually doing a 2.0 version of that report from last year. But you still don't have a lot of the top 340B hospitals that report. Why? Because they make so much money on these drugs and they mark them up, they don't want to show that. And the interesting thing is just recently, we've seen HHS hand out the first 2 fines to 2 Atlanta hospitals that basically have not reported. I think you'll see more pressure on HHS to hand out those fines, but frankly, if a hospital is making $350 million, $400 million a year, which some of the top hospitals are in 340B discounts, getting a fine of $2 million, $3 million a year is the price of doing business.
But this hospital transparency data is really waking a lot of people up as to how much money these hospitals are making on 340B and not literally passing the discounts on to patients, or using that to advance charity care. In many cases, their charity care has gone as their profits from 340B have gone up.
Study Highlights Significant Increases in Utilization, Spending on DMD Drugs in Medicaid
May 17th 2024The findings add to recent research on the growing utilization, expenditure, and prices of Duchenne muscular dystrophy (DMD) therapies in the current landscape, an area health care policy could potentially address.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Panel Addresses Minority Physician Shortage, Maternal Health at Senate Committee Hearing
May 15th 2024The senate hearing held by the US Senate Committee on Health, Education, Labor, and Pensions, led by Sen. Bernie Sanders (I, Vermont), chairman of the committee, and ranking member Sen. Bill Cassidy, MD, (R, Louisiana), addressed the critical issue of physician and health care worker shortages, as well as the maternal health crisis, in the US.
Read More
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Bleeds and Resource Use in Hemophilia B: Retrospective Observational Study
May 15th 2024This real-world US study describes individuals with hemophilia B who experience bleeds despite factor replacement therapy and quantifies the associated comorbidity and health care resource utilization burden.
Read More
A new study highlights significant disparity in reimbursement rates across states between hospitals and Medicare; the first patient to receive a genetically modified pig kidney has died; research examines outcomes of over 500 patients receiving medication abortion pills by mail.
Read More